Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

The execs at Haleon, a huge multinational consumer products company, ought to take a good look in the mirror. That is, unless misleading, sleazy marketing is in their mission statement. In that case, ...

That brand is more than just a logo - it’s your company’s ... of consumer marketing can be brought into the B2B pharmaceutical world. If GSK were to make a John Lewis-esque Christmas ad ...

The new money means that iTeos can now fund its activities through 2027, including the start of multiple phase 3 studies of belrestotug in combination with GSK ... and Logos Capital, as well ...

Bearish flow noted in GSK (GSK) Pharma with 1,131 puts trading, or 2x expected. Most active are Mar-25 33 puts and Jan-26 35 puts, with total volume in those strikes near 730 contracts. The Put/Call ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...

Q4 2024 dividend of 16p declared; 61p FY 2024; 64p expected for 2025. GSK (GSK) now intends to commence a GBP 2B share buyback programme, to be ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

GSK stock rocketed Wednesday after the pharma titan raised its 2031 sales outlook to north of $50 billion.Please watch the ...